EMAIL THIS PAGE TO A FRIEND

Arthritis & rheumatology (Hoboken, N.J.)

Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.


PMID 24504799

Abstract

The rationale for blocking interleukin-6 (IL-6) in rheumatoid arthritis (RA) lies chiefly in the proinflammatory effect of this cytokine. Few studies have evaluated the consequences of anti-IL-6 receptor (IL-6R) antibody treatment on Treg cells. This study was undertaken to elucidate the mechanism of action of anti-IL-6R antibody treatment by studying the effects on Treg cells in an experimental arthritis model and in patients with RA. Mice with collagen-induced arthritis (CIA) were treated with a mouse anti-IL-6R antibody (MR16-1), and changes in Treg, Th1, and Th17 cells were assessed at key time points during the course of the disease. Peripheral blood from 15 RA patients was collected on day 0 and after 3 months of tocilizumab treatment for flow cytometry analysis of Th17 and Treg cells. In MR16-1-treated mice, Th17 cell frequencies were unchanged, whereas Treg cell frequencies were increased. The Treg cell phenotype showed marked changes, with an increase in the frequency of CD39+ Treg cells in the lymph nodes and spleen. Interestingly, similar CD39+ Treg cell expansion was observed in RA patients who were tocilizumab responders at 3 months, with no change in Th17 cell frequency. Moreover, fluorescence-activated cell-sorted CD39+ Treg cells from responder RA patients were functionally able to suppress the proliferation of conventional T cells. In both CIA and RA, the frequency of functionally suppressive CD39+ Treg cells is increased as a result of anti-IL-6R treatment, whereas Th17 cells are unaffected. The modification of Treg cell frequency and phenotype may be one of the mechanisms involved in the therapeutic effect of IL-6 blockade in RA.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA000440
Anti-CD45 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
PRS4877
Anti-IL-17 (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS4887
Anti-IL-17 (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2502114
Anti-IL17A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2502115
Anti-IL17A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA052258
Anti-IL17A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
GW21465 Anti-PTPRC antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
A6237 Apyrase from potato, recombinant, expressed in Pichia pastoris, ATPase ≥1000 units/mg protein, lyophilized powder
SAB4700471 Monoclonal Anti-CD45 antibody produced in mouse, clone MEM-28, purified immunoglobulin, buffered aqueous solution
AMAB90518
Monoclonal Anti-CD45 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0159, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90519
Monoclonal Anti-CD45 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0160, purified immunoglobulin, buffered aqueous glycerol solution
SAB4700587 Monoclonal Anti-CD45 antibody produced in rat, clone EM-05, purified immunoglobulin, buffered aqueous solution
SAB3701439
Monoclonal Anti-IL-17A antibody produced in mouse, clone 4H1524.1, purified immunoglobulin
SAB3701458
Monoclonal Anti-IL-17A antibody produced in rat, clone 20B4.G10.F5, purified immunoglobulin
SAB4700649 Monoclonal Anti-PTPRC antibody produced in mouse, clone IVA103, purified immunoglobulin, buffered aqueous solution